Profiles of medication literacy and associated factors among young and middle-aged hypertensive patients in China: A latent profile analysis Authors: Rui Wang, Chongbin Liu, Yu Wang, Xiaopu Shi, Siwen Ma, Gaokai Li, Gang Wang, Wejdan Shahin, Wejdan Shahin, Wejdan Shahin, Wejdan Shahin, Wejdan Shahin, Ilse Bloom, Wejdan Shahin, Wejdan Shahin, Ilse Bloom, Fan Chen, Wejdan Shahin, Wejdan Shahin, Ilse Bloom, Fan Chen, Fan Chen, Wejdan Shahin, Wejdan Shahin, Ilse Bloom, Fan Chen, Fan Chen Published: 2026 ABSTRACT Improving medication literacy among individuals with hypertension has emerged as a significant public health issue. However, the heterogeneity of medication literacy and its association factors among young and middle-aged patients with hypertension has not yet been fully characterized. The current study aimed to identify distinct profiles of medication literacy in these population and to examine their associated factors, with the goal of informing targeted clinical interventions. A cross-sectional study was conducted with 544 consecutively recruited these hypertensive patients from two tertiary hospitals in China between July 15 and November 15, 2024. Researchers administered five validated instruments: a Demographic and Disease-Related Characteristics Questionnaire, the Revised Chinese Medication Literacy Scale for Hypertensive Patients (C-MLSHP-R), the Perceived Social Support Scale (PSSS), the General Self-Efficacy Scale (GSES), and the Brief Illness Perception Questionnaire (BIPQ). Latent profile analysis revealed three distinct profiles of medication literacy: low (35.3%), moderate (50.2%), and high (14.5%). Multivariate logistic regression further identified education level, per capita monthly household income, social support, self-efficacy, and illness perception as factors significantly associated with medication literacy (all p < 0.05). More specifically, lower education and lower income were associated with membership in the low literacy profile, while higher social support, higher self-efficacy, and more positive illness perception characterized the high literacy group. These results suggest preliminary stratified interventions approaches, including foundational education for patients with low-literacy patients, behavioral reinforcement for those with moderate literacy, and enhanced psychosocial support for socioeconomically disadvantaged groups. However, causal interpretations are precluded by the cross-sectional design, longitudinal studies are needed to validate these findings. 1. Introduction Currently, China is grappling with the escalating burden of hypertension. A recent study indicated 59% (aged 55–62) of women and 49% (aged 46–52) of men diagnosed with hypertension in 2019 [1]. An increasing prevalence of hypertension persists among young and middle-aged people, suggesting an increased risk of cardiovascular complications. What’s more, the focus on young and middle-aged adults is particularly warranted for several reasons. First, this age group represents a critical window for early intervention, as cardiovascular risk factors established during this period significantly influence later-life outcomes. Second, young and middle-aged hypertensive patients face unique challenges including work-related stress, family responsibilities in China. Third, these hypertensive patients demonstrate particular vulnerability due to three critical factors: heightened health risk perception deficits compared to older adults, inadequate self-management behaviors, and persistent misconceptions equating asymptomatic presentation with therapeutic non-necessity [2,3]. Hypertension prevalence in China has risen, while the awareness, treatment and control rates for hypertension remain relatively low [4]. Therefore, effective management of hypertension among young and middle-aged people is essential to prevent deterioration and complications, making it a primary concern in public health. Medication literacy is an individual’s ability to acquire, understand, communicate, compute, and process drug-specific information in order to make informed medication and health decisions that ensure safe and effective medication use [5]. Evidence substantiated its positive correlation with medication adherence and blood pressure control in hypertensive populations [6–8]. In recent years, most studies on medication literacy employed a “variable-centered” approach, assuming sample homogeneity and focusing on group characteristics [9]. However, this approach overlooks individual differences and group heterogeneity, potentially masking distinct subpopulations with unique medication literacy patterns that require tailored interventions. This study employs Bandura’s Social Cognitive Theory first articulated in 1986 [10], with particular emphasis on triadic reciprocal determinism and self-efficacy theory. Triadic reciprocal determinism conceptualizes environment, personal cognition, and behavior as interdependent components of a unified system. These elements interact dynamically, with behavior emerging as a product of the continuous interplay between cognitive processes and environmental contexts. Self-efficacy theory posits that individuals’ beliefs in their capabilities exert significant influence on behavioral outcomes. In the present study, medication literacy is operationalized as the behavioral component, social support as the environmental factor, and illness perception as the cognitive element. Latent profile analysis (LPA), a “person-centered” method, identifies group heterogeneity by analyzing shared response patterns and classifying individuals into distinct subgroups [11,12]. Unlike traditional cluster analysis, LPA offers several advantages: it uses maximum likelihood estimation for greater statistical rigor, provides probabilistic class membership rather than deterministic classification, and offers comprehensive model fit indices to guide class enumeration. This approach improves classification accuracy and captures subgroup characteristics, which is useful for guiding individualized clinical practice and achieving improved intervention outcomes, particularly for vulnerable groups [13]. Unfortunately, the heterogeneity of medication literacy among hypertensive patients, especially among the young and middle-aged people has yet to be explored. Therefore, this study used the LPA to explore the latent profile characteristics of medication literacy, with a specific focus on association factors of each subgroup, to provide evidence for developing targeted intervention strategies. 2. Methods 2.1 Participants This cross-sectional study enrolled 544 consecutively recruited hypertensive adults (aged 18–59 years) from two tertiary hospitals in a single-city of China between July 15 and November 15, 2024. The sample size was considered adequate based on Monte Carlo simulation studies for latent profile analysis [14]. The study protocol was approved by the Ethics Review Board of Huzhou University (No. 202240703, dated January 10, 2024). The inclusion criteria were as follows: (1) age 18–59 years, (2) confirmed hypertension diagnosis per 2024 Chinese Hypertension Management Guidelines [15], (3) current or recent (≤3 months) antihypertensive medication use, (4) adequate cognitive/communication capacity, and (5) written informed consent. Exclusion criteria included: (1) psychiatric comorbidities or severe hypertensive complications (e.g., encephalopathy, hypertensive crisis), (2) major systemic disorders (malignancy, recent cardiovascular/cerebrovascular events, end-stage renal disease), (3) secondary hypertension, and (4) participation in other hypertension trials within 30 days prior to the study. 2.2 Research tools and data collection The study incorporated five validated instruments: (1) a Demographic and Disease-Related Characteristics Questionnaire, (2) the Revised Chinese Medication Literacy Scale for Hypertensive Patients (C-MLSHP-R), (3) the Perceived Social Support Scale (PSSS), (4) the General Self-Efficacy Scale (GSES), and (5) the Brief Illness Perception Questionnaire (BIPQ). The C-MLSHP-R (18 items) operationalizes medication literacy through four domains: medication knowledge, medication attitude, medication skills, and medication behaviors [16]. The medication knowledge dimension includes four multiple-choice items, with one point awarded for each correct answer. The medication attitude dimension consists of three items, and the medication behavior dimension comprises four items, both rated on a 5-point Likert scale (0–4 points). Items A1-A3 are reverse-scored. The medication skill dimension contains seven items, with one point assigned for a correct answer and zero points for an incorrect answer or a response of “do not know.” The total scale score ranges from 0 to 51 points, with higher scores indicating a higher level of medication literacy among patients with hypertension. The PSSS is a 12-item self-report inventory comprising three domains: family support, friend support, and other support [11]. All items were rated using a 7-point Likert scale. The total scale score ranges from 12 to 84, with higher scores indicating a higher level of social support among patients. The GSES questionnaire consists of 10 items measured on a 4-point Likert scale ranging from 1 (“completely disagree”) to 4 (“completely agree”) [17]. Scale scores range from 10 to 40. Higher scores reflect a more positive perception and evaluation of one’s own capabilities. The BIPQ includes three dimensions: disease cognition, emotion and disease understanding [18]. It consists of 9 items, including 3 reverse-scored items, 5 forward-scored items, and 1 open-ended question, rated on a 0–10 scale.The scale ranges from 0 to 80. Higher scores indicate more negative disease perceptions and emotions. The reliability of the scales was assessed using Cronbach’s α coefficient in this study. The Cronbach’s α was 0.903 for the C-MLSHP-R, 0.921 for the PSSS, 0.916 for the GSES, and 0.892 for the BIPQ, all above 0.8, indicating good to excellent internal consistency. Participants were first informed about the confidentiality and content of the study. After providing written informed consent, participants voluntarily completed the questionnaires. Questionnaires were administered and returned on-site by five uniformly trained research assistants. For a small number of illiterate patients, a researcher read the content of the questionnaire aloud and completed it according to the patient’s wishes. The sample size for this study met the recommended threshold for cross-sectional analyses of this nature [14,19,20], which a minimum sample size of about 500 should lead to enough accuracy in identifying a correct number of latent profiles. Of the 573 questionnaires distributed, 29 were excluded as invalid, including 5 with missing data on core variables, 9 with obvious logical errors, and 15 with straight-lined responses (same answer for all items). 2.3 Data analysis Data were analyzed using SPSS 26.0 and Mplus 8.3. The four domain scores of the Revised Chinese Medication Literacy Scale for Hypertensive Patients (C-MLSHP-R) were entered as indicators in latent profile analysis. Measurement data were described as means and standard deviations, while count data were described using frequencies and composition ratios. A two-step approach was employed for the regression analysis. First, bivariate analyses (Chi-square tests for categorical variables and ANOVA for continuous variables) were conducted to identify candidate variables associated with medication literacy profiles. Subsequently, variables demonstrating statistical significance (P < 0.05) in the bivariate analyses, along with theoretically relevant sociodemographic confounders, were simultaneously entered into a multivariate multinomial logistic regression model to identify independent association factors while controlling for potential confounding effects. These covariates included age, sex, place of residence, occupational/work-related status, blood pressure monitoring, education level, per capita monthly household income, PSSS, GSES, and BIPQ. All covariates were retained in the final model regardless of statistical significance. Before model fitting, multicollinearity among predictors was assessed. Because occupational status and type of work were structurally overlapping, they were handled as occupational/work-related status to avoid collinearity and unstable parameter estimates. The high medication literacy profile was used as the reference category. Prior to conducting the regression, multicollinearity among the predictor variables was assessed using the Variance Inflation Factor (VIF). All VIF values ranged from 1.029 to 3.056, falling well below the conventional threshold of 5, indicating that multicollinearity did not bias the parameter estimates. Latent profile modeling was conducted using the robust Maximum Likelihood Estimator (MLR) in Mplus 8.3 to account for potential non-normality in the continuous indicators. The models were specified such that variances were freely estimated across profiles, while covariances between indicators were constrained to zero within classes (local independence assumption). Modeling began with a baseline model (one class), gradually increasing the number of classes and evaluating the model fit indices for each. To avoid local maxima, 500 random starts with 100 final stage optimizations were employed, and the best log-likelihood value was verified to be successfully replicated across starts [19]. The fit indicator criteria included: (1) Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC), and adjusted BIC (aBIC), where lower values indicate better fit; (2) entropy, where values closer to 1 indicate better classification accuracy; (3) Lo-Mendell-Rubin adjusted likelihood ratio test (LMR) and Bootstrap Likelihood Ratio Test (BLRT), with P < 0.05 indicating that a K-class model fits significantly better than a K-1 class model. All tests were performed using a two-sided with a significance level of 0.05. 3. Results 3.1 Demographic characteristics Of the 573 questionnaires distributed, 544 valid questionnaires were included, with an effective response rate of 94.94%. No missing data were observed for all variables entered into latent profile analysis and multinomial logistic regression. Table 1 presented the general characteristics of the 544 young and middle-aged patients with hypertension. 10.1371/journal.pone.0352857.t001Table 1Demographic and disease characteristics of each latent profile (n = 544).VariablesOverall (n = 544)P1: lowmedicationliteracyP2: moderatemedicationliteracyP3: highmedicationliteracyχ²/FP value(n = 192)(n = 273)(n = 79)Gender Male330 (60.7%)115 (59.9%)162 (59.3%)53 (67.1%)1.6140.446 Female214 (39.3%)77 (40.1%)111 (40.7%)26 (32.9%)Age (year) 18-40140 (25.7%)31 (16.1%)84 (30.8%)25 (31.6%)28.011<0.001 41-50218 (40.1%)73 (38.0%)105 (38.5%)40 (50.6%) 51-59186 (34.2%)88 (45.8%)84 (30.8%)14 (17.7%)Education Junior middle school and below324 (59.6%)160 (83.3%)149 (54.6%)15 (19.0%)103.077<0.001 Senior school or technical secondary school104 (19.1%)19 (9.9%)56 (20.5%)29 (36.7%) Junior college/ College degree or above116 (21.3%)13 (6.8%)68 (24.9%)35 (44.3%)Residence Urban378 (69.5%)110 (57.3%)203 (74.4%)65 (82.3%)22.620<0.001 Rural areas166 (30.5%)82 (42.7%)70 (25.6%)14 (17.7%)Occupation status On-the-job394 (72.4%)116 (60.4%)214 (78.4%)64 (81.0%)21.848<0.001 Jobless93 (17.1%)46 (24.0%)37 (13.6%)10 (12.7%) Retired57 (10.5%)30 (15.6%)22 (8.1%)5 (6.3%)Work type Mainly manual labor269 (49.4%)109 (56.8%)129 (47.3%)31 (39.2%)19.1230.001 Mainly mental labor236 (43.4%)63 (32.8%)127 (46.5%)46 (58.2%) Neither39 (7.2%)20 (10.4%)17 (6.2%)2 (2.5%)Marital status Married461 (84.7%)168 (87.5%)229 (83.9%)64 (81.0%)7.8040.137* Unmarried62 (11.4%)14 (7.3%)37 (13.6%)11 (13.9%) Divorced18 (3.3%)9 (4.7%)6 (2.2%)3 (3.8%) Widowed3 (0.6%)1 (0.5%)1 (0.4%)1 (1.3%)Medical insurance type Self-paying or other51 (9.4%)20 (10.4%)27 (9.9%)4 (5.1%)7.9270.244 New rural cooperative medical insurance42 (7.7%)21 (10.9%)18 (6.6%)3 (3.8%) Medical insurance for urban workers402 (73.9%)134 (69.8%)205 (75.1%)63 (79.7%) Medical insurance for urban residents49 (9.0%)17 (8.9%)23 (8.4%)9 (11.4%)The number of people who live together 1 or below130 (23.9%)40 (20.8%)73 (26.7%)17 (21.5%)2.4500.294 2 or above414 (76.1%)152 (79.2%)200 (73.3%)62 (78.5%)Per capita monthly household income (¥)** <5,000179 (32.9%)114 (59.4%)55 (20.1%)10 (12.7%)113.550<0.001 5,000-10,000230 (42.3%)58 (30.2%)142 (52.0%)30 (38.0%) >10,000135 (24.8%)20 (10.4%)76 (27.8%)39 (49.4%)History of hypertension (year) <5260 (47.8%)82 (42.7%)144 (52.8%)34 (43.0%)7.5760.108 5-10181 (33.3%)67 (34.9%)88 (32.2%)26 (32.9%) >10103 (18.9%)43 (22.4%)41 (15.0%)19 (24.1%)History of antihypertensives (year) <5303 (55.7%)101 (52.6%)163 (59.7%)39 (49.4%)5.7800.216 5-10149 (27.4%)58 (30.2%)70 (25.6%)21 (26.6%) >1092 (16.9%)33 (17.2%)40 (14.7%)19 (24.1%)BP monitoring Yes398 (73.2%)100 (52.1%)228 (83.5%)70 (88.6%)67.951<0.001 No146 (26.8%)92 (47.9%)45 (16.5%)9 (11.4%)Types of medications 1362 (66.5%)126 (65.6%)181 (66.3%)55 (69.6%)2.9010.574 2147 (27.0%)54 (28.1%)71 (26.0%)22 (27.8%) ≥ 335 (6.4%)12 (6.3%)21 (7.7%)2 (2.5%)Family history of hypertension Yes332 (61.0%)112 (58.3%)173 (63.4%)47 (59.5%)1.2940.524 No212 (39.0%)80 (41.7%)100 (36.6%)32 (40.5%)Medical background Yes96 (17.6%)28 (14.6%)56 (20.5%)12 (15.2%)3.1110.211 No448 (82.4%)164 (85.4%)217 (79.5%)67 (84.8%)Number of comorbidities 0328 (60.3%)112 (58.3%)164 (60.1%)52 (65.8%)2.6640.850 1165 (30.3%)64 (33.3%)81 (29.7%)20 (25.3%) 241 (7.5%)13 (6.8%)23 (8.4%)5 (6.3%) ≥310 (1.8%)3 (1.6%)5 (1.8%)2 (2.5%)Side effect of medication Yes203 (37.3%)77 (40.1%)94 (34.4%)32 (40.5%)1.9520.377 No341 (62.7%)115 (59.9%)179 (65.6%)47 (59.5%)PSSS(mean±SD)53.95 ± 10.7346.03 ± 8.0156.77 ± 9.3963.51 ± 7.88141.15<0.001GSES(mean±SD)26.78 ± 5.6022.84 ± 4.1428.08 ± 5.1331.85 ± 3.74128.49<0.001BIPQ(mean±SD)37.28 ± 12.5347.54 ± 8.2133.60 ± 10.7825.06 ± 8.02195.01<0.001* Fisher’s exact probability method.** US$1 equals ¥7.1793, exchange rate on 1 February 2025.PSSS, the Perceived Social Support Scale; GSES, the General Self-Efficacy Scale;BIPQ, the Brief Illness Perception Questionnaire. Demographic and disease characteristics of each latent profile (n = 544). * Fisher’s exact probability method. ** US$1 equals ¥7.1793, exchange rate on 1 February 2025. PSSS, the Perceived Social Support Scale; GSES, the General Self-Efficacy Scale; BIPQ, the Brief Illness Perception Questionnaire. 3.2 Latent profile analysis and characteristics of latent classes As shown in Table 2, while the AIC, BIC, and aBIC values continued to decrease with additional classes, model selection balanced statistical fit with parsimony, classification quality, and substantive interpretability [21]. The 4-profile model was not supported by the LMR test (P = 0.108), suggesting that the improvement in fit from three to four classes was not statistically significant. The 5-profile model yielded a class containing only 0.9% of the sample, below the recommended 5% threshold raising concerns about overfitting [21,22]. In contrast, the 3-profile model demonstrated excellent classification accuracy (entropy = 0.927; average posterior probabilities of 97.2%, 96.7%, and 97.9%, all exceeding 90%) and yielded theoretically coherent and clinically interpretable profiles. Therefore, the 3-profile solution was selected as the optimal model. The characteristics of the latent classes were detailed in Fig 1 and Table 3. Profile 1 (n = 192, 35.3%), characterized by consistently low scores across all items, was designated as “low medication literacy (Low C-MLSHP-R)”. Profile 2 (n = 273, 50.2%) exhibited moderate performance across domains, classified as “moderate medication literacy (moderate C-MLSHP-R)”. Profile 3 (n = 79, 14.5%) demonstrated uniformly high item scores, identified as “high medication literacy (High C-MLSHP-R)”. 10.1371/journal.pone.0352857.t002Table 2Fit statistics for profile structure (n = 544).No. of profilesAICBICaBICEntropyLMRBLRTLatent profile proportion (%)12915.4862949.8782924.483 __ __ __ __ 22167.0362222.9222181.6550.7890.008<0.0010.546/0.45431585.8791663.2601606.1210.927<0.001<0.0010.353/0.502/0.14541493.8931592.7691519.7580.9360.108<0.0010.357/0.143/0.053/0.44751437.8351558.2061469.3230.945<0.001<0.0010.449/0.355/0.009/0.053/0.134aBIC, adjusted BIC; AIC, Akaike information criterion; BIC, Bayesian information criterion; BLRT, bootstrap likelihood ratio test; LMR, Lo-Mendell-Rubin likelihood ratio test. Fit statistics for profile structure (n = 544). aBIC, adjusted BIC; AIC, Akaike information criterion; BIC, Bayesian information criterion; BLRT, bootstrap likelihood ratio test; LMR, Lo-Mendell-Rubin likelihood ratio test. 10.1371/journal.pone.0352857.t003Table 3Mean scores and standard deviation for each dimension of the three-profile model of medication literacy (n = 544).Profile 1Profile 2Profile 3Low medication literacy (n = 192)Moderate medication literacy (n = 273)High medication literacy (n = 79)M (SD)M (SD)M (SD)Medication knowledge1.26 ± 0.041.93 ± 0.022.88 ± 0.03Medication attitude1.47 ± 0.042.52 ± 0.033.30 ± 0.09Medication skills0.56 ± 0.010.66 ± 0.010.88 ± 0.01Medication behavior1.85 ± 0.022.68 ± 0.023.55 ± 0.02M = Mean; SD = Standard deviation. Mean scores and standard deviation for each dimension of the three-profile model of medication literacy (n = 544). M = Mean; SD = Standard deviation. Mean scores for each dimension of the three-profile model of medication literacy (n = 544). 3.3 Association factors of medication literacy Group comparisons identified differences in age, educational level, residence, occupational status, work type, per capita monthly household income, blood pressure monitoring, as well as PSSS, GSES, and BIPQ scores (e.g., Table 1). The latent profile membership (low, moderate, or high medication literacy) was used as the dependent variable. Demographic information, disease-related characteristics, variables that were statistically significant in bivariate analyses, and PSSS, GSES, and BIPQ scores were entered into a multinomial logistic regression model. The coding of the independent variables was detailed in Table 4. After adjustment for age, sex, place of residence, occupational/work-related status, blood pressure monitoring, education level, per capita monthly household income, PSSS, GSES, and BIPQ, several factors remained associated with medication literacy profiles (e.g., Table 5). Compared with the high medication literacy profile, patients with lower educational attainment, lower income, lower perceived social support, lower self-efficacy, and higher illness perception scores were more likely to be classified into the low medication literacy profile. The fully adjusted model also allowed assessment of non-significant covariates, which are now reported in Table 5. Compared to patients with a college degree or above (reference group), those with junior high school education or below had 6.55 times higher odds of belonging to the low medication literacy profile (OR = 6.553, 95% CI: 1.916–22.408) and 2.30 times higher odds of belonging to the moderate medication literacy profile (OR = 2.303, 95% CI: 1.042–5.093). Similarly, patients with a per capita monthly household income below 5,000 RMB had 3.84 times higher odds of low medication literacy compared to those earning above 10,000 RMB (OR = 3.842, 95% CI: 1.122–13.147). Each one-unit increase in social support (PSSS) was associated with a 12.3% reduction in the odds of low medication literacy (OR = 0.877, 95% CI: 0.835–0.921), and each one-unit increase in self-efficacy (GSES) was associated with an 18.8% reduction (OR = 0.812, 95% CI: 0.734–0.899). Conversely, each one-unit increase in negative illness perception (BIPQ) was associated with a 13.5% increase in the odds of low medication literacy (OR = 1.135, 95% CI: 1.081–1.192). It should be noted that some OR estimates (e.g., education: junior middle school and below) exhibited wide confidence intervals due to sparse cell counts in the high medication literacy profile (n = 79). These estimates should be interpreted with caution, and the direction of association rather than the precise magnitude is more informative in these cases. 10.1371/journal.pone.0352857.t004Table 4Assignment of independent variables in multiple logistic regression.VariablesAssignment of variablesLatent categoriesLow medication literacy = 1, moderate medication literacy = 2, high medication literacy = 3Age18-40 years = 1, 41–50 years = 2, 51–59 years = 3Degree of educationJunior high school and below=1, technical secondary school/senior high school = 2, junior college/college degree and above = 3ResidenceUrban = 1, rural = 2Occupational statusEmployed = 1, unemployed or jobless = 2, retired = 3Type of workMainly manual labor = 1, mainly mental labor = 2, neither = 3Average monthly household income<5,000 RMB = 1, 5,000-10,000 RMB = 2,>10,000 RMB = 3Monitored blood pressureMonitored = 1, not monitored = 2 Assignment of independent variables in multiple logistic regression. 10.1371/journal.pone.0352857.t005Table 5Multinomial logistic regression analysis of association factors (n = 544).VariableHigh medication literacy (Ref)Low medication literacyModerate medication literacyOR95%CIP ValueOR95%CIP ValueAge 41–50 years (Ref: 18–40 years)0.2390.072-0.7970.0200.1530.063-0.375<0.001Age 51–59 years (Ref: 18–40 years)0.3610.079-1.6590.1910.1460.040-0.5310.003Education(Ref: Junior college/ College degree or above)Junior middle school and below6.5531.916-22.4080.0032.3031.042-5.0930.039Senior school or technical secondary school3.3160.848-12.9670.0850.9510.473-1.9090.887Residence: rural (Ref: urban)0.3820.104-1.4060.1480.1800.056-0.5810.004Occupational status: jobless (Ref: on-the-job)36618831.40.000-Inf0.9956479488.70.000-Inf0.995Occupational status: retired (Ref: on-the-job)1.8880.139-25.6250.6331.2510.107-14.6350.858Per capita monthly household income(Ref: > 10,000 RMB)5,000 RMB3.8421.122-13.1470.0320.9190.352-2.3990.8625,000–10,000 RMB2.3070.818-6.5090.1141.5360.799-2.9500.198BP monitoring: No (Ref: Yes)9.8431.322-73.2720.0262.9520.422-20.6580.275PSSS0.8770.835-0.921<0.0010.9630.927-1.0000.049GSES0.8120.734-0.899<0.0010.8870.818-0.9620.004BIPQ1.1351.081-1.192<0.0011.0471.008-1.0870.017Note: High medication literacy was used as the reference group. Model adjusted for age, sex, residence, occupational status, blood pressure monitoring, education, income, PSSS, GSES, and BIPQ. Type of work was not simultaneously included because it was collinear with occupational status in the SAV. ORs for jobless and income <5,000 are unstable because the high-literacy group had zero cases in those categories. Consider category merging or penalized multinomial logistic regression.PSSS, the Perceived Social Support Scale; GSES, the General Self-Efficacy Scale.BIPQ, the Brief Illness Perception Questionnaire. Multinomial logistic regression analysis of association factors (n = 544). Note: High medication literacy was used as the reference group. Model adjusted for age, sex, residence, occupational status, blood pressure monitoring, education, income, PSSS, GSES, and BIPQ. Type of work was not simultaneously included because it was collinear with occupational status in the SAV. ORs for jobless and income <5,000 are unstable because the high-literacy group had zero cases in those categories. Consider category merging or penalized multinomial logistic regression. PSSS, the Perceived Social Support Scale; GSES, the General Self-Efficacy Scale. BIPQ, the Brief Illness Perception Questionnaire. 3.4 Sensitivity analysis Split-half cross-validation confirmed the stability of the 3-profile solution. In both random subsamples (n₁ = 272, n₂ = 272), the 3-profile model was identified as optimal based on the same criteria applied to the full sample. The models exhibited excellent classification accuracy in both subsamples (entropy = 0.904 and 0.920, respectively). More importantly, the tripartite structure (low, moderate, and high medication literacy) was successfully replicated, with profile proportions and domain-specific mean score patterns closely mirroring those of the full-sample analysis. These findings indicate that the 3-profile solution is robust and not an artifact of sample-specific characteristics. 4. Discussion Medication literacy is a key factor in determining the use of health-related information, promoting health, and improving the quality of life. However, in China, young and middle-aged patients with hypertension often exhibit suboptimal medication literacy and adherence [23,24]. Unlike previous investigations [25,26], this study is among the first to apply a person-centered approach and empirically focused on the characteristics of medication literacy among young and middle-aged Chinese hypertensive patients, thereby complementing the limitations of previous studies and offering a novel perspective for future research on medication literacy. This study revealed that the medication literacy score for young and middle-aged hypertensive patients was 28.78 ± 7.58, suggesting an intermediate level with significant potential for improvement. While scores marginally exceeded those reported in prior research [27], the discrepancy likely reflects differences in sample characteristics across studies (e.g., age range, regional healthcare access). Meanwhile, latent profile analysis identified three distinct medication literacy profiles: low (35.3%), moderate (50.2%), and high (14.5%) groups, establishing a tripartite classification of patient capabilities. Also, significant intergroup variations emerged across educational level, per capita monthly family income, PSSS, GSES, and BIPQ scores (Tables 1–3, Fig 1), confirming population heterogeneity. These findings deepen the understanding of medication literacy as a multifaceted construct and provide an empirical basis for tailoring interventions to specific patient subgroups. Consistent with Social Cognitive Theory, the identified medication literacy profiles suggest that medication literacy extends beyond knowledge acquisition. It reflects a dynamic interplay among cognitive factors (self-efficacy, illness perception), environmental influences (social support), and behavioral determinants. These profile-specific characteristics suggest tailored intervention strategies: low-literacy patients may benefit from foundational knowledge and skills training, moderate-literacy patients require reinforcement of positive attitudes and behaviors, and high-literacy patients could serve as peer educators or mentors. This theoretically grounded stratification moves beyond descriptive classification by highlighting specific pathways that could inform future intervention design. However, these recommendations are preliminary and hypothesis-generating, rather than clinical guidelines. In this study, patients with junior high school or below were significantly more likely to be categorized into low medication literacy groups (OR = 6.553) compared to their counterparts with higher educational attainment (e.g., Table 5). Consistent with research in other populations [28], lower education levels were associated with greater delays in seeking care and reduced participation in cardiovascular health programs. These findings align with previous studies showing that higher educational attainment correlates with better medication knowledge, more positive attitudes, and improved medication practices [29]. To address these educational disparities, tailored approaches such as patient-centered visual tools (e.g., graphical medication schedules, 3D animated vascular models) and short video-based instruction may help optimize knowledge retention in this population [30,31]. The study also found that individuals with monthly household incomes below 5,000 RMB demonstrated a significantly higher propensity for classification into the low medication literacy (OR = 3.842), highlighting their close association with medication literacy in these hypertensive patients. One possible explanation is that people with high incomes are willing to spend a lot of money on health care and health promotion and generally have a high educational level. This finding is consistent with other studies conducted in China which found that socioeconomically advantaged patients exhibited reduced psychosocial stressors but enhanced health maintenance behaviors (such as proactive engagement in preventive healthcare measures, increased frequency of clinical consultations and utilization of premium healthcare services) [32]. These findings underscored the imperative for nursing professionals to integrate socioeconomic status evaluations into comprehensive care frameworks. Aligned with a longitudinal analysis [33], this study also substantiated the social support systems was an association factor with medication literacy in hypertensive patients. In China, due to the intense pressure of work among young and middle-aged populations, which often brings challenges such as reduced social opportunities, loss of social roles. Therefore, these people also lack time and energy to care for them, their social support level will be further reduced. However, optimal social support provision facilitates both emotional comfort and health information accessibility, thereby fostering the development of medication literacy through dual channels. In addition, strengthening the support networks within families, such as enhancing emotional care and providing practical assistance from children and relatives, may provide significant protection against low medication literacy. Thus, nursing staff should implement routine social support assessments and develop family inclusive care protocols to optimize therapeutic alliances and medication literacy outcomes. Consistent with prior studies [17,18,34], this study found a significant positive correlation between patients’ self-efficacy scores and their medication literacy levels. Higher self-efficacy may foster a more resolute problem-solving attitude and better resistance to the negative impacts of health-related challenges. This also suggests that higher self-efficacy means patients gain a clearer understanding of their condition, feel a stronger sense of control, and find greater meaning in life, thereby promoting an improvement in medication literacy. Based on these findings, clinical nurses could consider strategically integrate self-efficacy assessments into routine health education protocols in these hypertensive patients. Encouraging patients with higher self-efficacy to serve as role models for those with lower self-efficacy may be beneficial. Additionally, helping patients establish milestones and regularly reflect on their disease experiences could further enhance self-efficacy and medication literacy. The findings of this study are consistent with those of previous studies that showed negative correlation between disease perception scores and medication literacy levels [35,36]. Higher levels of medication literacy facilitate enhanced understanding of disease potential risks and consequences, the knowledge and capabilities to take appropriate actions, thereby fostering a more objective and rational illness perception. At the same time, disease self-perception can provide information to formulators of public health policies so that they can take measures aimed at encouraging the practice, especially with regard to the low medication literacy of young and middle-aged hypertensive populations. The observed associations among social support, self-efficacy, illness perception, and medication literacy profiles are broadly consistent with Social Cognitive Theory. However, these cross-sectional associations do not establish causal directionality. This design precludes determination of whether these factors precede and influence medication literacy, whether medication literacy shapes these psychosocial attributes, or whether unmeasured confounders account for these relationships. For instance, low medication literacy may lead to suboptimal disease control, subsequently diminishing self-efficacy and amplifying negative illness perceptions. Longitudinal studies are warranted to elucidate these temporal relationships and empirically test the proposed theoretical model. These findings highlight the potential value of structured psychological evaluation protocols for routine nursing assessments. Specifically, attention could be given to patients with high illness perception scores, with the goal of alleviating negative emotions and fostering a more accurate understanding of their condition—potentially through cognitive behavioral therapy or structured educational interventions. Nurses may also encourage patients to take a more active role in learning about their medications as part of routine care. Limitations: This study provided valuable insights, but several limitations should be acknowledged. First, a small sample size and the exclusive recruitment of participants from a single city in China created geographical homogeneity and limited the generalizability, as regional variations in socioeconomic status, cultural practices, and healthcare infrastructure may influence medication literacy patterns. To enhance the generalizability and applicability of the findings, future studies should expand the participant pool to include hypertensive patients from different provinces and diverse cultural contexts in China. Second, the cross-sectional study design inherently precludes the establishment of causal relationships between variables and only verifies their associative relationships. Additionally, while the 3-profile model was identified as optimal, and the high entropy and posterior probabilities of our model mitigate classification error, the classify-then-analyze approach used in our regression models may still introduce some degree of bias in parameter estimates. Third, a small number of illiterate patients had their questionnaires completed by researchers following verbal administration, which may have introduced measurement bias or social desirability bias. Prospective longitudinal studies are warranted in the future to clarify the temporal relationships between variables and adopt more objective evaluation indicators to reduce the impact of bias on study results. Fourth, the relatively small sample size of the high medication literacy profile (n = 79) limited the number of covariates that could be reliably included in the multinomial logistic regression model. The sparse data in this subgroup led to wide confidence intervals for some OR estimates, particularly for education and income categories. Future studies with larger sample sizes are needed to provide more precise estimates and to allow for comprehensive covariate adjustment including demographic confounders such as age, sex, and place of residence. Finally, the focus on young and middle-aged hypertension patients limited the understanding of developmental trajectories in medication management competencies. More diverse samples are necessary for broader applicability of the results. 5. Conclusion Overall, this study identify distinct subgroup characteristics of medication literacy among young and middle-aged Chinese patients with hypertension. This classification also provide evidence of the heterogeneity of medication literacy within this population. Associated factors include education level, per capita monthly household income, social support, self-efficacy, and illness perception. These findings extend Social Cognitive Theory to medication literacy research by illustrating how personal, environmental, and behavioral factors differentiate patient subgroups, thereby contributing to the theoretical understanding of medication literacy development in the context of chronic disease. These findings may inform the development of tailored intervention programs aimed at enhancing medication literacy among young and middle-aged patients with hypertension. However, given the observational design and the methodological constraints discussed above, these recommendations should be regarded as preliminary and hypothesis-generating rather than evidence-based clinical guidelines. In practice, individualized interventions may be most beneficial when tailored to patients’ medication literacy profiles. Particular attention may be given to patients with low medication literacy, with a focus on associated factors such as education level, household income, social support, self-efficacy, and illness perception. 29 Dec 2025 -->PONE-D-25-50007-->-->Profiles of medication literacy and its predictors among young and middle-aged hypertensive patients in China: a latent profile analysis-->-->PLOS One Dear Dr. Wang, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== The manuscript presents a timely and methodologically sound application of latent profile analysis to explore heterogeneity in medication literacy among young and middle-aged patients with hypertension. The person-centred analytical approach is a clear strength and offers added value beyond traditional variable-centred methods. However, in its current form, the manuscript requires substantial refinement to ensure interpretive caution, conceptual clarity, and stronger translational relevance. The primary areas requiring revision relate to how the study scope and findings are framed and interpreted. The manuscript would benefit from clearer definition and justification of the target population early in the Introduction, along with a more explicitly articulated research focus that guides the reader through the study rationale. While the analytical methods are appropriate, several sections of the Results and Discussion employ language that may be interpreted as implying causality, despite the cross-sectional design. A more cautious interpretive stance is needed, particularly when describing associations between medication literacy profiles and sociodemographic or psychosocial variables. Greater transparency is also required regarding the generalisability of the findings. The exclusive recruitment from tertiary hospitals in an economically developed region, combined with the focus on a single age group and reliance on self-reported measures, constrains the extent to which the results can be extrapolated to broader populations. These issues should be addressed more explicitly in the Limitations section and reframed as opportunities for future research, including longitudinal designs and recruitment across diverse geographic and healthcare contexts. ============================== Please submit your revised manuscript by Feb 12 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Wejdan Shahin Academic Editor PLOS One Journal requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed: https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2022.987526/full In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed. 3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section. 4. Thank you for stating the following financial disclosure: “This study was funded by Natural Science Foundation of Huzhou city, Zhejiang province, China (2022YZ44).” Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 5. Thank you for stating the following in the Funding Section of your manuscript: “This study was funded by Natural Science Foundation of Huzhou city, Zhejiang province, China (2022YZ44).” We note that you have provided funding information that is currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: “This study was funded by Natural Science Foundation of Huzhou city, Zhejiang province, China (2022YZ44).” Please include your amended statements within your cover letter; we will change the online submission form on your behalf. 6. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process. 7. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #2: Yes ********** -->2. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #2: Yes ********** -->3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: Much appreciated for giving me the opportunity for this review, this study innovatively uses latent class analysis to explore group heterogeneity in drug literacy, going beyond the limitations of traditional variable-centric analysis. This“Human-centered” approach can more truly reflect the diversity and complexity of the patient population, and has important methodological value for developing precise and personalized clinical intervention strategies. But there are some areas for improvement, which should be more fully addressed in the“Limitations” of the discussion section, it is pointed out that the conclusions of this study are mainly applicable to patients in tertiary hospitals in economically developed areas similar to Zhejiang province in China. In conclusion or future research directions, it is suggested that follow-up studies should recruit samples from more diverse areas (such as Midwestern Sectional Figure Skating Championships, urban and rural communities) to verify the generalizability of the findings of this study. More cautious language should be used when discussing partial interpretation of the results, describing“Influencing factors” or“Predictors” as“Relevant factors” or“Association factors”, avoid words that imply causality. The overall language of the manuscript is fluent, but there are minor grammatical problems or repetitions in individual sentences. It is recommended that the final version be thoroughly polished in English. For example, the abstract and the introduction are somewhat repetitive and could be further refined. Reviewer #2: Dear Authors, Please find my brief and constructive comments below. Introduction Review The introduction is clear; however, defining young and middle-aged patients at the outset would help readers. In addition, briefly clarifying the research gap and stating a clear research question would make the study’s focus easier to follow. Methodology Review The study is valuable and provides useful findings; however, a few points could be clarified to improve transparency. As the study uses a cross-sectional design, the results reflect associations only and do not allow for causal interpretations. Moreover, reliance on self-reported questionnaires means that some responses may not fully reflect patients’ actual experiences or behaviors. Focusing on one age group and a single geographic region may also limit the generalizability of the findings. Clearly acknowledging these points in the limitations section would strengthen the manuscript. Results Review The study is well conducted; however, the choice of the number of profiles involves some degree of judgment. Therefore, the findings should be interpreted with caution, particularly given the cross-sectional design and limited sample. Acknowledging the potential impact of self-reported data on result accuracy would further strengthen the results section. Discussion Review The discussion is clear and relevant, but it could be strengthened by explaining why factors such as education, income, social support, and self-efficacy influence medication literacy. Linking the identified profiles more clearly to real clinical practice, with simple examples of tailored interventions, would improve practical relevance. Limitations Review The limitations are well presented; however, they could be more explicit regarding how the homogeneous sample and reliance on self-reported data may affect interpretation and generalizability. Framing each limitation as a clear direction for future research would further strengthen this section. Conclusion Review The conclusion summarizes the findings well; however, it could be more impactful by emphasizing the practical benefits of identifying medication literacy profiles and by offering one or two clear, actionable recommendations for clinical practice or health policy. ********** -->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 14 Jan 2026 Dear editors, We would like to submit the revised manuscript entitled “Profiles of medication literacy and associated factors among young and middle-aged hypertensive patients in China: a latent profile analysis (PONE-D-25-50007)”, which we wish to be considered for publication in “PLOS ONE”. We also described all authors listed have contributed to the work, all authors have read, approved and agreed to submit the revised manuscript to “PLOS ONE”, no part of the work has been published before. This study was funded by Natural Science Foundation of Huzhou city, Zhejiang province, China (2022YZ44). The funder role is writing the original draft and investigation. We have considered all issues mentioned in the academic editor and Reviewers’ comments carefully and have made correction which we hope meet with approval. Revised portion are marked in blue in the revised manuscript with track changes paper. Thank you and best regards, yours sincerely, Chongbin Liu Corresponding author: School of Medicine, Huzhou University, Huzhou, People’s Republic of China, 313000 E-mail address: liuchongbin1972@126.com. Submitted filename: Response to reviewers.doc 17 Feb 2026 -->PONE-D-25-50007R1-->-->Profiles of medication literacy and associated factors among young and middle-aged hypertensive patients in China: a latent profile analysis-->-->PLOS One Dear Dr. wang, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== Please ensure that the second reviewer comments are addressed properly. ============================== Please submit your revised manuscript by Apr 03 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Wejdan Shahin Academic Editor PLOS One Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #1: All comments have been addressed Reviewer #2: (No Response) ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #2: Yes ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #2: Yes ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: Dear Academic Editor and Authors, Thank you for the opportunity to review this manuscript, “Profiles of medication literacy and associated factors among young and middle-aged hypertensive patients in China: a latent profile analysis.”The study is a multicenter cross-sectional survey of 544 hypertensive adults aged 18–59 years recruited from two tertiary hospitals (July 15, 2024–November 15, 2024) and applies latent profile analysis (LPA) to identify medication-literacy subgroups, followed by logistic regression to examine associated factors. Below I put forward 3 points to modify the proposal, for your reference� 1.Data Availability statement appears internally inconsistent; this must be corrected to meet PLOS expectations for reproducibility. In the submission materials, “No—some restrictions will apply” is selected, yet the accompanying statement indicates that all data are contained within the manuscript/Supporting Information. 2.Methods are not yet sufficiently reproducible for LPA + regression (inputs, missing data, and classification uncertainty). The manuscript indicates use of SPSS 26.0 and Mplus 8.3 and lists fit indices (AIC/BIC/aBIC, entropy, LMR, BLRT), but key implementation details are still missing (e.g., which variables were entered into LPA—18 items vs. domain scores; whether variables were standardized; random starts; missing-data handling). 3.Interpretation should be more cautious given cross-sectional design and potential information bias from assisted completion. The study is cross-sectional, sampled from tertiary hospitals, and a subset of respondents had questionnaires read aloud and completed by researchers, which may introduce measurement or social-desirability bias. The study addresses an important applied question and the LPA-derived profiles are promising.However, I recommend making the above 3 changes, primarily to (i) resolve the Data Availability inconsistency, (ii) strengthen reproducibility and appropriately handle classification uncertainty, and (iii) tighten causal language and bias/generalizability discussion in line with the design. Reviewer #2: Reviewer Comments Introduction The introduction addresses an important topic; however, it would benefit from stronger conceptual grounding. Key variables such as self-efficacy and illness perception are discussed, yet they are not clearly situated within an established theoretical framework, which somewhat limits the scientific coherence of the study. In addition, the rationale for adopting a latent profile approach is introduced rather abruptly, with limited discussion of the shortcomings of prior variable-centered analyses. A more explicit justification of this methodological choice would strengthen the argument. Finally, the decision to focus on young and middle-aged adults (18–59 years) requires clearer justification, particularly in terms of why this specific age group warrants distinct investigation. Methods While the methodological structure is generally appropriate, several aspects require clarification. The manuscript does not provide a formal power analysis or detailed justification for sample adequacy in the context of latent profile analysis, where class stability and model complexity are important considerations. Furthermore, essential modeling details related to the latent profile procedure—such as estimation methods, model assumptions, and safeguards against local maxima—are not sufficiently described, which limits reproducibility. The regression strategy also requires clearer explanation. The criteria for variable selection and control of potential confounders are not fully articulated, and there is no indication that multicollinearity among predictors was assessed. Finally, the recruitment of participants from only two tertiary hospitals in a single city raises concerns regarding external validity and potential selection bias. Results The selection of the three-profile solution would benefit from a more comprehensive justification, particularly given that fit indices continued to improve with additional classes. A clearer discussion of the trade-offs underlying this decision is warranted. In addition, latent class membership was used in subsequent regression analyses without addressing Potential classification uncertainty may influence the accuracy of parameter estimates. The results section places strong emphasis on statistical significance, while offering limited discussion of effect sizes and their clinical implications. Overall, the presentation remains largely descriptive, with limited analytical depth and no robustness or sensitivity analyses to support the stability of the identified profiles. Discussion The discussion summarizes the findings effectively but would benefit from deeper analytical engagement. Much of the section reiterates results rather than exploring underlying mechanisms or situating the findings within broader theoretical perspectives. Given the cross-sectional design, some interpretations and practice-oriented recommendations should be framed more cautiously to avoid implying causal relationships. A more explicit reflection on methodological limitations, particularly those related to the latent profile approach, would also strengthen this section. Limitations and Conclusion Although general limitations are acknowledged, there is limited discussion of issues specific to the modeling approach, such as model selection uncertainty or classification error. Moreover, the connection between stated limitations and the strength of the conclusions could be more clearly articulated. The conclusion largely restates the main findings without clearly highlighting the study’s theoretical or methodological contribution. Practical recommendations appear somewhat stronger than what can be supported by an observational design and would benefit from more cautious framing. Abstract The abstract would benefit from a more balanced structure. Clinical implications appear somewhat overstated given the study design, and key limitations are not mentioned. Additionally, methodological details receive relatively greater emphasis than interpretive insights, which could be better prioritized in a concise summary. ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 1 Apr 2026 Dear Reviewers, We appreciate the opportunity to revise our manuscript titled “Profiles of medication literacy and associated factors among young and middle-aged hypertensive patients in China: a latent profile analysis (PONE-D-25-50007R1)” and are grateful for the insightful comments provided by the reviewers. Those comments are all valuable and very helpful for revising and improving our paper, as well as the important guiding significance to our researches. In the following, we have provided detailed responses to each of the reviewers’ comments. Revised portion are marked in blue in the revised manuscript with track changes paper. We have tried our best to make all the revisions clear, and we hope that the revised manuscript meets the requirements for publication. Submitted filename: Response_to_reviewers_auresp_2.doc 16 Apr 2026 -->PONE-D-25-50007R2-->-->Profiles of medication literacy and associated factors among young and middle-aged hypertensive patients in China: a latent profile analysis-->-->PLOS One-->--> Dear Dr. wang, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. The manuscript has been further evaluated by two reviewers, and their comments are available below. Could you please carefully revise the manuscript to address all comments raised? Please submit your revised manuscript by May 31 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. --> If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Ilse Bloom Staff Editor PLOS One Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #2: Yes ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #2: Yes ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: The study revolves around the heterogeneity of drug literacy in young and middle-aged patients with hypertension, adopts a cross-sectional design, consecutively enrolls 544 patients from two tertiary hospitals, and conducts a potential profile analysis using the four dimensions of C-MLSHP-R, and analyzes the relationship between drug literacy and risk factors, and further test the related factors with multinomial Logistic regression. The authors identified three subtypes of drug literacy: low, moderate, and high, and reported that education level, family income, social support, self-efficacy, and disease perception were significantly associated with subtype attribution. According to PLOS ONE's criteria of“Only judging scientific rigor”, the advantages of this paper are clear research questions, complete ethical approval and informed consent, and more complete modeling details than common cross-sectional studies, the random starting point, VIF and split-half sensitivity analysis are supplemented, which shows that the authors have made efforts to improve the reproducibility and stability of the results. However, there are still some key issues that affect the judgment of publication: 1� data availability statements are still not enough to satiPLOSPOne ONE's reproducibility requirements.Data availability information is still unclear from the current manuscript package, and the authors themselves admit to previous inconsistencies during the round-trip review. Recommendation: Please include additional subjects in flow charts or tables and at least report: (a) specific decision rules for 29 invalid questionnaires; (b) the proportion missing for each core variable/scale; (C) LPA versus treatment of missingness used in regression; (d) in the absence of missing data, state explicitly“No missing data for variables entered into LPA/regression”. 2)The external validity is limited, while the practical recommendations are still slightly strong. The sample was collected from two tertiary hospitals in the same city in China, and a small number of illiterate patients were filled in by the offspring, which may introduce selection bias and information bias. Although the authors mention this in their limitations, the conclusion“Provides a theoretical basis for the development of intervention programs for caregivers” and“Should be individualized,” which is slightly forward in the hierarchy of evidence. 3)On the basis of univariate significant variables and theoretically relevant confounders, multinomial Logistic regression was entered; Table 4 also encodes variables such as age, place of residence, occupational status, type of work, and blood pressure monitoring. However, Table 5 ultimately reported only five categories of variables: education, income, PSSS, GSES, and BIPQ, complete adjustment for age, place of residence, occupation, type of work, blood pressure monitoring, or theoretical confounders such as sex was not seen. 4)Language and grammar errors are still more, it is recommended to Polish professional English. 5)There are spelling and typographical errors in the table. table1 and table 5. 6)It is suggested that the scale reliability index of the current sample should be supplemented in the text 7)References and format details should be unified. 8)In the results section, it is suggested to reduce“Statistically significant” repetitive statements and increase model interpretation Reviewer #2: The manuscript has improved and most comments have been addressed well. Only one minor point: Please briefly clarify the sample size justification for the latent profile analysis in the Methods section. Overall, the manuscript is suitable for publication after this minor revision. ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: Yes: Abdulelah Al-Ganad ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 18 May 2026 Dear the academic editor and Reviewers, We appreciate the opportunity to revise our manuscript titled “Profiles of medication literacy and associated factors among young and middle-aged hypertensive patients in China: a latent profile analysis (PONE-D-25-50007R2)” and are grateful for the insightful comments provided by the reviewers. Those comments are all valuable and very helpful for revising and improving our paper, as well as the important guiding significance to our researches. In the following, we have provided detailed responses to each of the reviewers’ comments. Revised portion are marked in blue in the revised manuscript with track changes paper. We have tried our best to make all the revisions clear, and we hope that the revised manuscript meets the requirements for publication. The main corrections in the paper and the responses to the reviewer’s comments are as following: Responses to the reviewer’s comments: Reviewer #1: The study revolves around the heterogeneity of drug literacy in young and middle-aged patients with hypertension, adopts a cross-sectional design, consecutively enrolls 544 patients from two tertiary hospitals, and conducts a potential profile analysis using the four dimensions of C-MLSHP-R, and analyzes the relationship between drug literacy and risk factors, and further test the related factors with multinomial Logistic regression. The authors identified three subtypes of drug literacy: low, moderate, and high, and reported that education level, family income, social support, self-efficacy, and disease perception were significantly associated with subtype attribution. According to PLOS ONE’s criteria of “Only judging scientific rigor”, the advantages of this paper are clear research questions, complete ethical approval and informed consent, and more complete modeling details than common cross-sectional studies, the random starting point, VIF and split-half sensitivity analysis are supplemented, which shows that the authors have made efforts to improve the reproducibility and stability of the results. However, there are still some key issues that affect the judgment of publication: 1. Data availability statements are still not enough to sati PLOSONE’s reproducibility requirements. Data availability information is still unclear from the current manuscript package, and the authors themselves admit to previous inconsistencies during the round-trip review. Recommendation: Please include additional subjects in flow charts or tables and at least report: (a) specific decision rules for 29 invalid questionnaires; (b) the proportion missing for each core variable/scale; (C) LPA versus treatment of missingness used in regression; (d) in the absence of missing data, state explicitly “No missing data for variables entered into LPA/regression”. Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. We have supplemented additional subjects in results portion in this text. 2. The external validity is limited, while the practical recommendations are still slightly strong. The sample was collected from two tertiary hospitals in the same city in China, and a small number of illiterate patients were filled in by the offspring, which may introduce selection bias and information bias. Although the authors mention this in their limitations, the conclusion “Provides a theoretical basis for the development of intervention programs for caregivers” and “Should be individualized,” which is slightly forward in the hierarchy of evidence. Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. We have corrected the language in the conclusion, which is slightly forward in the hierarchy of evidence. 3. On the basis of univariate significant variables and theoretically relevant confounders, multinomial Logistic regression was entered; Table 4 also encodes variables such as age, place of residence, occupational status, type of work, and blood pressure monitoring. However, Table 5 ultimately reported only five categories of variables: education, income, PSSS, GSES, and BIPQ, complete adjustment for age, place of residence, occupation, type of work, blood pressure monitoring, or theoretical confounders such as sex was not seen. Response: Thank you for this important and constructive comment. We agree that the covariates included in the multinomial logistic regression model should be reported more transparently. In the revised manuscript, we re-ran the multinomial logistic regression using a fully adjusted model. In addition to education level, per capita monthly household income, PSSS, GSES, and BIPQ, we included theoretically relevant sociodemographic and disease-management covariates, including age, sex, place of residence, occupational/work-related status, and blood pressure monitoring. During model re-specification, we found that occupational status and type of work were highly overlapping in the dataset, particularly because retired participants were simultaneously coded as “retired/neither” for type of work. To avoid multicollinearity and unstable parameter estimates, we handled these two variables as occupational/work-related status in the adjusted model. All retained covariates were kept in the model regardless of statistical significance. We have revised the Statistical analysis section to clarify the model-building strategy, added sex/gender coding to the variable assignment table, and expanded Table 5 to present the fully adjusted multinomial logistic regression results, including both statistically significant and non-significant covariates. The Results section and table footnotes have also been revised accordingly. 4. Language and grammar errors are still more, it is recommended to Polish professional English. Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. We have tried our best to improve the language and grammar errors in this manuscript and made some changes in the manuscript. 5. There are spelling and typographical errors in the table. table1 and table 5. Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. We have checked and corrected the spelling and typographical errors in the table1 and table 5. 6. It is suggested that the scale reliability index of the current sample should be supplemented in the text. Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. The reliability of the scales was assessed using Cronbach’s α coefficient in this study. We have supplemented in the text. 7. References and format details should be unified. Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. We have checked and corrected references and format details in the text. 8. In the results section, it is suggested to reduce“Statistically significant” repetitive statements and increase model interpretation. Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. In the results section, we have reduced the “Statistically significant” repetitive statements. Reviewer #2: The manuscript has improved and most comments have been addressed well. Only one minor point: Please briefly clarify the sample size justification for the latent profile analysis in the Methods section. Overall, the manuscript is suitable for publication after this minor revision. Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. We have clarified the sample size justification for the latent profile analysis in the Methods section. We tried our best to improve the manuscript and made some changes in the manuscript. These changes will not influence the content and framework of the paper. And here we did not list the changes but marked in blue in the revised paper. We appreciate for Editors/Reviewers’ warm work earnestly, and hope that the correction will meet with approval. Once again, thank you very much for your comments and suggestions. Best regards! Yours sincerely, Rui Wang Submitted filename: Response_to_reviewers_auresp_3.doc 26 May 2026 -->PONE-D-25-50007R3-->-->Profiles of medication literacy and associated factors among young and middle-aged hypertensive patients in China: a latent profile analysis-->-->PLOS One Dear Dr. wang, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jul 10 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. --> If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Fan Chen Academic Editor PLOS One Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments: While the manuscript has undergone proper revision, please carefully revise it further following the expert review comments. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #2: Yes ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #2: Yes ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: No ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: 1.Use “moderate medication literacy” consistently instead of alternating between “medium” and “moderate.” Replace full-width symbols such as “�” with standard mathematical symbols. 2.Use χ² or “Chi-square” instead of “X2.” 3.Explain the scoring range and direction for each scale and each C-MLSHP-R domain. 4.Please check all DOI formatting; at least one DOI appears to contain an extra space. Avoid speculative statements in the Discussion unless clearly marked as possible explanations. For example, “Maybe people with high incomes…” should be rewritten in formal academic language. 5.The funding statement should include whether the funder had any role in study design, data collection and analysis, decision to publish, or manuscript preparation. 6.Please avoid overstating external validity. Since the sample was recruited from two tertiary hospitals in one city, the study should be described as a two-hospital, single-city, hospital-based cross-sectional study. Overall, the manuscript has a clear research question and uses an appropriate person-centered method. The three-profile solution appears plausible based on the reported fit indices and sensitivity analysis. Nevertheless, the unresolved data availability issue, unstable multinomial regression results, inconsistencies in model reporting, and remaining language problems prevent acceptance in the present form. I recommend minor revision. Reviewer #2: Reviewer’s comments Thank you for the authors’ efforts in revising the manuscript. The paper has clearly improved, and most of the previous comments have been addressed. I only have a few minor suggestions that may help improve the clarity and transparency of the manuscript before final acceptance. 1-Sample size justification for LPA The sample size is mentioned as adequate, but it would be helpful if the authors briefly clarify why 544 participants are sufficient for latent profile analysis. 2-Data availability Please provide a clearer Data Availability Statement, including the repository name, DOI, accession number, or link. If the data cannot be shared openly, the reason should be briefly explained. 3-Invalid questionnaires and missing data The explanation of the 29 excluded questionnaires is clear, but it may be better placed in the Methods section or shown in a simple participant flow chart. 4-Table 5 and unstable ORs Some odds ratios in Table 5 appear unstable because of zero cases in certain categories. The authors may either address this statistically, for example by merging sparse categories or using penalized multinomial logistic regression, or clearly mention that these estimates should be interpreted with caution. 5-Discussion and practical recommendations The intervention-related recommendations are useful, but they should be expressed more cautiously. Please clarify that these recommendations are preliminary and hypothesis-generating, rather than clinical guidelines. 6-Generalizability Please clarify that although the sample size may be adequate for LPA, the recruitment from two hospitals in one city may limit the generalizability of the findings. Recommendation: Accept after minor revisions. ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: Yes: Abdulelah Al-Ganad ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. --> 2 Jun 2026 Responses to the reviewer’s comments: Reviewer #1: 1. Use “moderate medication literacy” consistently instead of alternating between “medium” and “moderate.” Replace full-width symbols such as “�” with standard mathematical symbols. Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. We have corrected these imperfection in the revised manuscript with track changes. 2.Use χ² or “Chi-square” instead of “X2.” Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. We have also corrected these imperfection in the revised manuscript with track changes. 3.Explain the scoring range and direction for each scale and each C-MLSHP-R domain. Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. We have supplemented the scoring range and direction for each scale and each C-MLSHP-R domain in the revised manuscript with track changes. 4. Please check all DOI formatting; at least one DOI appears to contain an extra space. Avoid speculative statements in the Discussion unless clearly marked as possible explanations. For example, “Maybe people with high incomes…” should be rewritten in formal academic language. Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. We have also corrected DOI formatting and speculative statements in the revised manuscript with track changes. 5. The funding statement should include whether the funder had any role in study design, data collection and analysis, decision to publish, or manuscript preparation. Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. We have supplemented the funding statement in the title page in the revised manuscript with track changes. 6. Please avoid overstating external validity. Since the sample was recruited from two tertiary hospitals in one city, the study should be described as a two-hospital, single-city, hospital-based cross-sectional study. Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. We have also corrected these imperfection in the revised manuscript with track changes. Reviewer #2: Thank you for the authors’ efforts in revising the manuscript. The paper has clearly improved, and most of the previous comments have been addressed. I only have a few minor suggestions that may help improve the clarity and transparency of the manuscript before final acceptance. 1. Sample size justification for LPA The sample size is mentioned as adequate, but it would be helpful if the authors briefly clarify why 544 participants are sufficient for latent profile analysis. Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. Actually, in our paper, the references (14, 19 and 20) are all shown that “best-practice and review results concluded that a minimum sample size of about 500 should lead to enough accuracy in identifying a correct number of latent profiles”. 2. Data availability Please provide a clearer Data Availability Statement, including the repository name, DOI, accession number, or link. If the data cannot be shared openly, the reason should be briefly explained. Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. We have supplemented the data availability statement in the title page in the revised manuscript with track changes. 3. Invalid questionnaires and missing data The explanation of the 29 excluded questionnaires is clear, but it may be better placed in the Methods section or shown in a simple participant flow chart. Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. The explanation of the 29 excluded questionnaires have placed in the Methods section in the revised manuscript with track changes. 4. Table 5 and unstable ORs Some odds ratios in Table 5 appear unstable because of zero cases in certain categories. The authors may either address this statistically, for example by merging sparse categories or using penalized multinomial logistic regression, or clearly mention that these estimates should be interpreted with caution. Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. As the reviewer noted that some OR values in Table 5 exhibit wide confidence intervals. This phenomenon is attributable to data sparsity in the high medication literacy profile (Profile 3, n = 79). This sparse data situation leads to quasi-complete separation in logistic regression, where the maximum likelihood estimator becomes unstable, producing inflated OR values and extremely wide confidence intervals. We acknowledge this limitation and have taken the following steps in the revised manuscript: a) Added cautionary interpretation in Results: It should be noted that some OR estimates (e.g., education: junior middle school and below) exhibited wide confidence intervals due to sparse cell counts in the high medication literacy profile (n = 79). These estimates should be interpreted with caution, and the direction of association rather than the precise magnitude is more informative in these cases." b) Added acknowledgment in Limitations: “Fourth, the relatively small sample size of the high medication literacy profile (n = 79) limited the number of covariates that could be reliably included in the multinomial logistic regression model. The sparse data in this subgroup led to wide confidence intervals for some OR estimates, particularly for education and income categories. Future studies with larger sample sizes are needed to provide more precise estimates and to allow for comprehensive covariate adjustment including demographic confounders such as age, sex, and place of residence”. 5. Discussion and practical recommendations The intervention-related recommendations are useful, but they should be expressed more cautiously. Please clarify that these recommendations are preliminary and hypothesis-generating, rather than clinical guidelines. Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. We have supplemented the statement in the revised manuscript with track changes. 6. Generalizability Please clarify that although the sample size may be adequate for LPA, the recruitment from two hospitals in one city may limit the generalizability of the findings. Response: We would like to express our sincere gratitude to the reviewer for your insightful comments and valuable feedback. We have supplemented the statement in the manuscript. Once again, thank you very much for your comments and suggestions. Best regards! Yours sincerely, Rui Wang Submitted filename: Response_to_reviewers_auresp_4.doc 16 Jun 2026 Profiles of medication literacy and associated factors among young and middle-aged hypertensive patients in China: a latent profile analysis PONE-D-25-50007R4 Dear Dr. Wang, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Fan Chen Academic Editor PLOS One Additional Editor Comments (optional): The author has made satisfactory revisions based on the reviewers' comments. The manuscript is recommended for acceptance. Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #2: Yes ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #2: Yes ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: Thank you for the opportunity to review the revised manuscript. The manuscript has improved compared with the previous version, and several concerns have been addressed. However, I think some important issues still need to be resolved before the manuscript can be considered suitable for publication in PLOS ONE. The research question is clear and appropriate for a cross-sectional observational study. The manuscript focuses on identifying medication literacy profiles among young and middle-aged patients with hypertension and examining associated factors. The use of latent profile analysis is generally suitable for the person-centered objective of the study. The authors report key model fit indices, including AIC, BIC, aBIC, entropy, LMR, and BLRT, and provide a rationale for selecting the three-profile solution. The revised manuscript has improved in transparency. The authors added scoring ranges for the scales, reported internal consistency coefficients, clarified the exclusion of invalid questionnaires, added a data availability statement, and acknowledged limitations related to cross-sectional design and limited generalizability. Reviewer #2: I appreciate the authors’ efforts in revising the manuscript. Overall, I feel that they have responded well to the reviewers’ comments and have improved the manuscript clearly. I have no major remaining concerns. The manuscript only needs minor language polishing and some Word/formatting corrections before final acceptance. Recommendation: Accept after minor language and formatting corrections. ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: Yes: Abdulelah Al-Ganad ********** PONE-D-25-50007R4 PLOS One Dear Dr. Wang, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Fan Chen Academic Editor PLOS One